[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
News From the Centers for Disease Control and Prevention
September 12, 2007

Notice to Readers: New Medication for Severe Malaria Available Under an Investigational New Drug Protocol

JAMA. 2007;298(10):1156. doi:10.1001/jama.298.10.1156

MMWR. 2007;56:769-770

On June 21, 2007, CDC's Investigational New Drug Application (IND) for intravenous artesunate went into effect. This IND allows for use of an investigational antimalarial medication (intravenous artesunate) under a protocol entitled “Intravenous Artesunate for Treatment of Severe Malaria in the United States.” Intravenous artesunate can be used only under the provisions of this IND protocol because it is not a drug approved by the Food and Drug Administration (FDA). Artesunate is in the class of medications known as artemisinins, which are derivatives from “quing hao,” or sweet wormwood plant (Artemisia annua). Only the CDC Drug Service and CDC Quarantine Stations will be permitted to release the medication for use under this IND protocol.